In June 2024, the U.S. Department of Commerce and the International Trade Commission (ITC) issued a final affirmative determination in the ‘double remedy’ (anti-dumping and countervailing duty) investigation on hard gelatin capsules from China, concluding that these imports have caused material injury to the U.S. domestic industry. This ruling paves the way for the imposition of substantial anti-dumping and countervailing duties on Chinese-origin capsules. Hard gelatin capsules are widely used as essential excipients in pharmaceuticals and dietary supplements. The investigation was initiated following petitions filed by U.S. capsule manufacturers alleging that Chinese exporters sold products below fair market value and benefited from government subsidies, thereby undercutting domestic producers and eroding their market share and profitability. The final determination will significantly impact Chinese capsule exporters, potentially prompting them to diversify into other markets or establish overseas production facilities to circumvent tariffs. This case also reflects the escalating trade tensions between the U.S. and China in the pharmaceutical supply chain, highlighting broader geopolitical and economic realignments in global manufacturing. Chinese firms are advised to enhance compliance, increase product value-added, and actively leverage WTO mechanisms to safeguard their interests.
2024年6月，美国商务部和国际贸易委员会（ITC）对原产于中国的硬质胶囊产品作出‘双反’（反倾销和反补贴）产业损害终裁，认定中国出口的硬质胶囊对美国国内产业造成实质性损害。该裁决意味着美国将正式对中国相关产品征收高额反倾销和反补贴税。硬质胶囊广泛用于药品、保健品等封装，是医药产业链中的关键辅料。此次调查源于美国部分胶囊制造商的申诉，称中国产品以低于公平价值的价格大量出口，并受益于政府补贴，导致美国本土企业市场份额下降、利润受损。终裁结果将影响中国多家胶囊生产企业对美出口，可能促使企业转向其他国际市场或通过海外设厂规避关税。同时，这也反映出中美在医药供应链领域的贸易摩擦持续升级，凸显全球产业链重构背景下的地缘经济博弈。中国企业需加强合规管理、提升产品附加值，并积极利用WTO规则维护自身权益。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/17850.html